PT-141 has became one of the most purchased peptides in recent years. But what makes this chemical so popular among other research chemicals? Stay with me for a while and I will blow your mind with PT-141 facts that you probably until now was not aware of.
AFFILIATE LINKS WITHIN THIS ARTICLE
In order to be able to provide high quality content, we publish 1 or 2 affiliate links with the intension of funding our writing. This does not in any way affect you our reader. It is perfectly safe to click such links and the companies are 100% legit and safe to purchase from. Thank you for your understanding.
Where to Find The Very Best PT-141 Buy
We know of most of the renown peptides players in the USA and abroad and as with any niche, there’s good and bad to be found everywhere. There is however one company that seem to outshine all of their competitors. Take a closer look at Peptide Sciences PT-141 Buy here and take advantage of their high quality research chemicals.
Introducing Peptide Sciences Of California USA
Peptides Sciences is one of the peptide labs that have been in business for the longest period. A completely independent company that actually manufacture their own peptides from their fully equipped laboratory with one of the largest ranges of high quality peptides we have ever seen.
What Is So Good About Peptide Sciences PT-141?
According to a recent report from CNN , on June 21, 2019, the US Food and Drug Administration (FDA) approved the drug Vyleesi ( syn. Bremelanotide, PT-141, bremelanotide), which increases sexual desire in women with low libido .
PT-141 is a synthetic cyclic heptapeptide analogous to α-MSH (α-melanocyte-stimulating hormone), an agonist of melanocortin receptors, in particular MC 1 R and MC 4 R, and an active metabolite of melanotan II [3, 4]. Bremelanotide has the following structure:
Ac-Nle-cyclo- (Asp-His-D-Phe-Arg-Trp-Lys) -OH
The drug is intended for the treatment of premenopausal women and / or with hypoactive sex drive disorder, in whom lack of interest in sex can lead to significant stressful experiences.
Vyleesi (Palatin Technologies and AMAG Pharmaceuticals) injectable bremelanotide is recommended to be injected subcutaneously in the abdomen or thigh with a pen containing 1.75 mg PT-141 (equivalent to 1.89 mg bremelanotide acetate) in 0.3 ml solution, not less than 45 minutes before the intended sexual intercourse . The drug has 100% bioavailability. The half-life is on average 2.7 hours. Excretion of PT-141 from the body in the form of hydrolysis products is carried out with urine (64.8%) and feces (22.8%).
According to AMAG spokeswoman Sarah Connors , the drug will go on sale in September 2019, but the company has yet to determine pricing or funding information.
In studies conducted on healthy women with sexual arousal disorder, it was found that women who received bremelanotide experienced a significant increase in rates of sexual arousal, as well as an increase in the incidence of sexual activity and the number of orgasms. Reported side effects following bemelanotide administration were nausea, hot flashes and headaches [2, 5]. However, women who experienced nausea while taking the drug generally continued to use bremelanotide because for them “the benefit outweighed the problem of tolerance”. PT-141 has successfully completed Phase II and III clinical trials, in which more than 2 thousand patients participated in total . PT-141 is contraindicated in patients with uncontrolled hypertension or unidentified cardiovascular disease.
Sheryl Kingsberg, clinical psychologist and head of behavioral medicine at the Cleveland Medical Center Clinical Hospital, participated in clinical trials of the drug and was a consultant to AMAG and Palatin Technologies, says that “sexual dysfunction deeply affects a woman’s self-esteem, her image body, her self-confidence and her relationships ”.
Experts argue that this type of sexual dysfunction is the most common type of sexual dysfunction among women, approximately 8 to 10% . The FDA’s decision to approve the drug gives clinicians another tool to help these women. “No matter how good the psychotherapy is, how good the relationship is, how good their beliefs and values about sexuality and health are, there are a huge number of women I cannot help because of a biological problem,” says Kingsberg. So, she added, it looks like depression, which has an established biological background that is driving the development of drug therapy.
Bremelanotide is not the first drug approved for the treatment of sexual dysfunction in women. For example, flibanserin, marketed under the brand name Addyi (Sprout Pharmaceuticals), was approved in August 2015. However, the drug was not widely used, in part because women could not take it with alcohol or if they had health problems. There is no alcohol interaction data for PT-141. It is worth noting that by slowing down gastric motility, bremelanotide reduces the bioavailability of some orally administered drugs, such as naltrexone and indomethacin .
Another difference between the drugs is that Addyi oral tablet is taken once a day, while patients can take bremelanotide as needed. Some people mistakenly consider PT-141 “female viagra”, but Viagra acts on the blood vessels, and bremelanotide acts directly on the receptors in the brain.
According to experts, in severe cases of female sexual dysfunction, even the “modest effect” of PT-141 can be very significant for a number of women who have used many other treatment options to no avail.